Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This study will evaluate the safety and efficacy of ertugliflozin (MK‐8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.
Epistemonikos ID: 73bdd4de8361013a5f4828ed5f53883c8109310a
First added on: May 22, 2024